October neuroscience and Alzheimer’s-focused developments reinforce the digital cognitive-assessment growth story after strong H1Revenuegrowth.
On 9 November 2026, CRISM Therapeutics (LSE:CRTX) is in focus as investors assess the latest company-specific catalyst and what it could mean for the next stage of the business. The immediate reason for attention is crism therapeutics remains in focus around its oncology-focused therapeutic …
Recent board and investor updates, including a leading-industry-figure chair appointment, have refocused attention on commercial execution.
On 9 November 2026, Futura Medical (LSE:FUM) is in focus as investors assess the latest company-specific catalyst and what it could mean for the next stage of the business. The immediate reason for attention is board change and formal sale-process progress have put futura …
The molecular diagnosticsBusinessremains in focus around product adoption, regulatory progress and commercial partnerships.
On 9 November 2026, GENinCode (LSE:GENI) is in focus as investors assess the latest company-specific catalyst and what it could mean for the next stage of the business. The immediate reason for attention is investor attention remains on genincode's genomic testing platform and the …
On 9 November 2026, Kooth (LSE:KOO) is in focus as investors assess the latest company-specific catalyst and what it could mean for the next stage of the business. The immediate reason for attention is kooth remains in focus as investors assess the pace of …
5 November first pharmaceutical agreement for EpiSwitch Orion, following a delayed-settlement update earlier in November.
On 9 November 2026, Proteome Sciences (LSE:PRM) is in focus as investors assess the latest company-specific catalyst and what it could mean for the next stage of the business. The immediate reason for attention is recent clinical chemoproteomics contract wins and the september interim …
On 9 November 2026, Provexis (LSE:PXS) is in focus as investors assess the latest company-specific catalyst and what it could mean for the next stage of the business. The immediate reason for attention is investor focus remains on provexis's fruitflow platform, licensing relationships and …